secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0000950170-22-022696
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics Q3: $1.8M revenue, $3.9M net loss; cash $35.9M funds through 2023
-------------------------------------------------------------------------------

- Cash and investments $35.9M as of Sep 30; sufficient to fund operations through end of 2023.
- Q3 2022 revenue of $1.8M from clinical material sales to licensee Wugen; no revenue in prior year.
- Net loss $3.9M in Q3 2022 vs $4.1M in Q3 2021; R&D flat at $2.7M, G&A up 23% to $1.7M.
- Three clinical sites activated for HCW9218 Phase 1b/2 in advanced pancreatic cancer; first patient dosed Oct 17.
- Purchased new HQ in Miramar, FL for ~$10M, financed with $6.5M loan at 5.75% interest.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000095017022022696/0000950170-22-022696-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000095017022022696/hcwb-20221107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-022696

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer